4D Pharma plc, of Leeds, U.K., and the University of Texas MD Anderson Cancer Center inked a collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings. The deal initially will assess lead candidate MRx-0518 as a potential treatment for solid tumors. Financial terms were not disclosed.